Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena’s Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company’s vision and strategy.

“I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and leadership,” said Daniel G. Welch, Chair of Prothena’s Board of Directors. “The entire board of director

See Full Page